Table 1.
Cancer type and summary repertoire features for 22 individuals receiving CTLA-4 monotherapy.
| Category | Subdefinition | Responder | Non-responder |
|---|---|---|---|
| Cancer type | Prostate | 2 | 4 |
| Melanoma | 7 | 6 | |
| Adenocarcinoma | 2 | 0 | |
| Not indicated | 0 | 1 | |
| Total | 11 | 11 | |
| Repertoire features | Clones detected | 32,916 (5,168–56,231) | 30,015 (5,894–58,222) |
| TCR convergence | 0.022 (0.006–0.092) | 0.008 (0.002–0.019) | |
| Clonality | 0.24 (0.055–0.376) | 0.133 (0.055–0.327) |
Summary repertoire features and sample annotations for cohort. Each individual was profiled via the Oncomine TCRB-LR Assay at a single baseline timepoint using 25 ng of cDNA derived from PBL total RNA. Repertoire feature values indicate the average and range for responders and non-responders.